Concordance between clinical trial data use request proposals and corresponding publications: A cross-sectional study
- PMID: 40396503
- PMCID: PMC12095927
- DOI: 10.1177/17407745241304355
Concordance between clinical trial data use request proposals and corresponding publications: A cross-sectional study
Abstract
Background/AimsThe reuse of clinical trial data available through data-sharing platforms has grown over the past decade. Several prominent clinical data-sharing platforms require researchers to submit formal research proposals before granting data access, providing an opportunity to evaluate how published analyses compare with initially proposed aims. We evaluated the concordance between the included trials, study objectives, endpoints, and statistical methods specified in researchers' clinical trial data use request proposals to four clinical data-sharing platforms and their corresponding publications.MethodsWe identified all unique data request proposals with at least one corresponding peer-reviewed publication as of 31 March 2023 on four prominent clinical trial data sharing request platforms (Vivli, ClinicalStudyDataRequest.com, the Yale Open Data Access Project, and Supporting Open Access to Researchers-Bristol Myers Squibb). When data requests had multiple publications, we treated each publication-request pair as a unit. For each pair, the trials requested and analyzed were classified as fully concordant, discordant, or unclear, whereas the study objectives, primary and secondary endpoints, and statistical methods were classified as fully concordant, partially concordant, discordant, or unclear. For Vivli, ClinicalStudyDataRequest.com, and Supporting Open Access to Researchers-Bristol Myers Squibb, endpoints of publication-request pairs were not compared because the data request proposals on these platforms do not consistently report this information.ResultsOf 117 Vivli publication-request pairs, 76 (65.0%) were fully concordant for the trials requested and analyzed, 61 (52.1%) for study objectives, and 57 (48.7%) for statistical methods; 35 (29.9%) pairs were fully concordant across the 3 characteristics reported by all platforms. Of 106 ClinicalStudyDataRequest.com publication-request pairs, 66 (62.3%) were fully concordant for the trials requested and analyzed, 41 (38.7%) for study objectives, and 35 (33.0%) for statistical methods; 20 (18.9%) pairs were fully concordant across the 3 characteristics. Of 65 Yale Open Data Access Project publication-request pairs, 35 (53.8%) were fully concordant for the trials requested and analyzed, 44 (67.7%) for primary study objectives, and 25 (38.5%) for statistical methods; 15 (23.1%) pairs were fully concordant across the 3 characteristics. In addition, 26 (40.0%) and 2 (3.1%) Yale Open Data Access Project publication-request pairs were concordant for primary and secondary endpoints, respectively, such that only one (1.5%) Yale Open Data Access Project publication-request pair was fully concordant across all five characteristics reported. Of three Supporting Open Access to Researchers-Bristol Myers Squibb publication-request pairs, one (33.3%) was fully concordant for the trials requested and analyzed, two (66.6%) for primary study objectives, and two (66.6%) for statistical methods; one (33.3%) pair was fully concordant across all three characteristics reported by all platforms.ConclusionAcross four clinical data sharing platforms, data request proposals were often discordant with their corresponding publications, with only 25% concordant across all three key proposal characteristics reported by each platform. Opportunities exist for investigators to describe any data-sharing request proposal deviations in their publications and for platforms to enhance the reporting of key study characteristic specifications.
Keywords: Clinical trials; data sharing; transparency.
Conflict of interest statement
Declaration of conflicting interestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: J.S.R., C.P.G., J.D.R., H.M.K., and J.D.W. are members of the YODA Project leadership team and receive support from Johnson & Johnson to support data sharing through the YODA project. J.S.R. is supported by the FDA, Arnold Ventures, AHRQ, and NHLBI and was an expert witness at the request of Relator’s attorneys, the Greene Law Firm, in a qui tam suit alleging violations of the False Claims Act and Anti-Kickback Statute against Biogen Inc. that was settled in September 2022. C.P.G. has received research funding from the NCCN Foundation (Astra-Zeneca) and Genentech. K.C. and S.B. are current employees and shareholders of Johnson & Johnson. J.D.R receives support from the FDA and Arnold Ventures. J.W. is a former employee and current shareholder of Johnson & Johnson and an Independent Board of Director and Shareholder for Becton Dickinson and Structure Therapeutics. J.W. is also a consultant for Galapagos NV. H.M.K. received options for Element Science and Identifeye and payments from F-Prime for advisory roles. He is a co-founder of and holds equity in Hugo Health, Refactor Health, and ENSIGHT-AI. He is associated with research contracts through Yale University from Janssen, Kenvue, and Pfizer. J.D.W. is supported by the FDA and Arnold Ventures. J.D.W. previously served as a consultant to Hagens Berman Sobol Shapiro LLP and Dugan Law Firm APLC.
Figures
Similar articles
-
Characteristics of available studies and dissemination of research using major clinical data sharing platforms.Clin Trials. 2021 Dec;18(6):657-666. doi: 10.1177/17407745211038524. Epub 2021 Aug 18. Clin Trials. 2021. PMID: 34407656 Free PMC article. Review.
-
Supporting open access to clinical trial data for researchers: The Duke Clinical Research Institute-Bristol-Myers Squibb Supporting Open Access to Researchers Initiative.Am Heart J. 2016 Feb;172:64-9. doi: 10.1016/j.ahj.2015.11.002. Epub 2015 Nov 14. Am Heart J. 2016. PMID: 26856217 Review.
-
Sharing of clinical trial data and results reporting practices among large pharmaceutical companies: cross sectional descriptive study and pilot of a tool to improve company practices.BMJ. 2019 Jul 10;366:l4217. doi: 10.1136/bmj.l4217. BMJ. 2019. PMID: 31292127 Free PMC article.
-
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217. Cochrane Database Syst Rev. 2022. PMID: 36321557 Free PMC article.
-
Data-Sharing Statements Requested from Clinical Trials by Public, Environmental, and Occupational Health Journals: Cross-Sectional Study.J Med Internet Res. 2025 Feb 7;27:e64069. doi: 10.2196/64069. J Med Internet Res. 2025. PMID: 39919275 Free PMC article.
References
-
- Medicine Io. Sharing Clinical Trial Data: Maximizing Benefits, Minimizing Risk. Washington, DC: The National Academies Press, 2015, p.304. - PubMed
-
- Kiley R, Peatfield T, Hansen J, et al. Data Sharing from Clinical Trials — A Research Funder’s Perspective. N Engl J Med 2017; 377: 1990–1992. - PubMed
-
- The World Health Organization. Developing Global Norms for Sharing Data and Results during Public Health Emergencies, http://www.who.int/medicines/ebola-treatment/data-sharing_phe/en/ (2015). - PMC - PubMed
-
- 2023 NIH Data Management and Sharing policy, https://oir.nih.gov/sourcebook/intramural-program-oversight/intramural-d... (2023).
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous